Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q3 2024 · 10-Q
Revenue$159.30M$159.30M+16.5% vs Q3 2023 Net Income$9.34M$9.34M−54.8% vs Q3 2023 EPS Diluted$0.27$0.27−49.1% vs Q3 2023 Gross Profit$96,794,000+20.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flowderived-$8,999,000N/M Free Cash Flowderived-$9,243,000N/M Margins · derivedGross margin60.8%+2.0 pt vs Q3 2023
Operating margin21.9%−11.1 pt vs Q3 2023
Net margin5.9%−9.2 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 7, 2024 · 38 d after period end